Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
March 05, 2024 08:30 ET
|
FN Media Group LLC
PALM BEACH, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer...
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
February 29, 2024 08:45 ET
|
AIM ImmunoTech Inc.
Company continues progress across Ampligen® clinical development programs Growing body of promising data demonstrates Ampligen’s potential to address multiple high-value indications OCALA, Fla.,...
FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results
February 20, 2024 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2023 financial results on Monday, February 26 after the market close....
AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
February 14, 2024 08:55 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the first subject has been dosed at Erasmus Medical Center (“Erasmus...
FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024
February 05, 2024 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host Part I of a virtual KOL investor event series on Tuesday, February 13, 2024 at 10:30 AM...
FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer
January 25, 2024 07:00 ET
|
FibroGen, Inc.
Pamrevlumab has now completed Stage 2 of the trial and topline data from this registration study in ~175 pamrevlumab treated patients is anticipated in 2Q 2024Pamrevlumab is the first experimental arm...
Metastatic Non-Small Cell Lung Cancer Market to Surge with a Potential USD 45 Billion Valuation by 2032, Reveals New Comprehensive Analysis
January 24, 2024 10:28 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Non-Small Cell Lung Cancer - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's...
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
January 24, 2024 09:10 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Jan. 24, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has received authorization from the Erasmus Medical Center...
Oncology Nutrition Market Experiences Growth with Rise in Personalized and Immuno-nutrition Trends
January 22, 2024 21:28 ET
|
Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Oncology Nutrition Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The recent comprehensive analysis within...
AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer
January 22, 2024 08:55 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Jan. 22, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the first subject has been enrolled at Erasmus Medical Center...